Skip Navigation


Rheumatology Advance Access originally published online on May 25, 2008
Rheumatology 2008 47(7):1070-1072; doi:10.1093/rheumatology/ken186
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
47/7/1070    most recent
ken186v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Belloli, L.
Right arrow Articles by Marasini, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Belloli, L.
Right arrow Articles by Marasini, B.
Related Collections
Right arrow Systemic Sclerosis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Myocardial involvement in systemic sclerosis

L. Belloli1, N. Carlo-Stella1, G. Ciocia2, A. Chiti2, M. Massarotti1 and B. Marasini1

1Rheumatology Unit and 2Nuclear Medicine Unit, IRCCS Humanitas Clinical Institute, University of Milan, Milan, Italy.

Correspondence to: N. Carlo-Stella, Rheumatology Unit, IRCCS Humanitas Clinical Institute, University of Milan, Italy. E-mail: nickics{at}libero.it


  Abstract

Objective. To identify clinical and/or laboratory characteristics that could be risk factors for myocardial microvascular involvement in patients with SSc.

Methods. Twenty-one SSc patients, clinically silent for cardiovascular disease, were consecutively evaluated for myocardial perfusion defects through 99m-Tc sestamibi gated myocardial perfusion SPECT with a stress–rest protocol.

Results. Eight patients (38%) had myocardial perfusion defects. Perfusion defects were related to skin scores (P < 0.0001), digital ulcers (P = 0.02) and oesophageal involvement (P = 0.046). A trend for anti-Scl 70 antibody positivity was observed in these patients (P = 0.09). Three SPECT-positive patients had re-establishment of normal myocardial perfusion after a course of prostanoid therapy. There were no significant associations between myocardial involvement and age, sex, diffuse/limited SSc, duration of RP or lung involvement.

Conclusions. Myocardial perfusion defects in SSc patients are frequent, and the presence of severe skin thickness, digital ulcers and perhaps oesophageal involvement might warrant screening for myocardial involvement. Further studies are necessary to evaluate the effect of prostanoid therapy on myocardial perfusion.

KEY WORDS: Myocardial perfusion, Systemic sclerosis, Prostanoid therapy

Submitted 8 January 2008; revised version accepted 10 April 2008.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.